M. Alexander Otto, PA, MMS April 18, 2023 The US Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge) for reducing infections and hastening neutrophil recovery for blood cancer patients aged 12 years and older who are undergoing allogeneic umbilical cord blood stem cell transplants. Omidubicel is made from umbilical cord donor stem cells that are processed with nicotinamide,...
Tag: <span>blood cancer patients</span>
Post
New CAR T-cell immunotherapy shows promising results for treating blood cancer patients
by King’s College London UCART19 cellular kinetics and correlation with clinical response. A, Graphical representation of UCART19 kinetic profile in PB of patients with B-ALL in the CALM study. B, Individual UCART19 kinetic profiles of adult patients with B-ALL by best overall response (BOR). C, From left to right: UCART19 AUC0-28 (AUC between day 0 and...
Post
Breakthrough in overcoming drug resistance provides new hope for blood cancer patients
by University of South Australia Credit: Pixabay/CC0 Public Domain South Australian scientists have made a significant breakthrough in overcoming drug resistance in acute myeloid leukemia (AML), a rare and devastating blood cancer that kills most patients within a few years. In a new study published in the hematology journal Blood, researchers from UniSA and SA Pathology’s...
Post
Response to COVID-19 vaccines varies widely in blood cancer patients
THE MOUNT SINAI HOSPITAL / MOUNT SINAI SCHOOL OF MEDICINE New York, NY (June 28, 2021) – Patients with a type of blood cancer called multiple myeloma had a widely variable response to COVID-19 vaccines–in some cases, no detectable response–pointing to the need for antibody testing and precautions for these patients after vaccination, according to...
Post
Low on antibodies, blood cancer patients can fight off COVID-19 with T cells
by Perelman School of Medicine at the University of Pennsylvania Credit: Pixabay/CC0 Public Domain Antibodies aren’t the only immune cells needed to fight off COVID-19—T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19 published in Nature Medicine....
Post
Research breakthrough for high-risk blood cancer patients
by Candy Gibson, University of South Australia Cells indicating multiple myeloma, the second most common blood cancer. Credit: University of South Australia South Australian researchers are hoping to improve the outcome of patients with multiple myeloma after identifying a new protein associated with the most aggressive form of the disease. A team from the University of South Australia...